OBJECTIVE: To determine the association between hypogonadal symptoms and total serum testosterone levels in middle-aged and elderly men (aged > 40 years), and to identify whether there exists a clear-cut discriminatory threshold of total testosterone below which the probability of hypogonadal symptoms increases. METHODS: We retrospectively reviewed the charts of 360 men who presented to an outpatient men's health clinic with a chief complaint of low testosterone. Sexual, psychological, and physical symptoms were evaluated using the androgen deficiency in the aging male (ADAM) questionnaire. Serum levels of total testosterone were collected on the same day on which men completed their ADAM questionnaires. We performed the univariate (t test, chi-square, and binary logistic regression) and multivariate analyses (binary logistic regression) to evaluate the total testosterone threshold and the symptoms that predicted a low-testosterone level. RESULTS: A cluster of symptoms: 1 sexual (decreased libido), 1 psychological (decreased energy), and 3 physical (decreased strength or endurance, decreased ability to play sports, and falling asleep after dinner) were most associated with total serum testosterone levels of ≤ 300 ng/dL. The threshold testosterone serum levels that were associated with an increased prevalence of these hypogonadal symptoms ranged from 320 to 375 ng/dL. On multivariate analysis, age, but not symptoms on the ADAM questionnaire, predicted a total testosterone level of < 300 ng/dL. CONCLUSION: A distinct constellation of hypogonadal symptoms exists at various serum testosterone levels. Consequently, identification of the thresholds for specific symptom management will be critical in establishing patient-centered treatment algorithms.
OBJECTIVE: To determine the association between hypogonadal symptoms and total serum testosterone levels in middle-aged and elderly men (aged > 40 years), and to identify whether there exists a clear-cut discriminatory threshold of total testosterone below which the probability of hypogonadal symptoms increases. METHODS: We retrospectively reviewed the charts of 360 men who presented to an outpatientmen's health clinic with a chief complaint of low testosterone. Sexual, psychological, and physical symptoms were evaluated using the androgen deficiency in the aging male (ADAM) questionnaire. Serum levels of total testosterone were collected on the same day on which men completed their ADAM questionnaires. We performed the univariate (t test, chi-square, and binary logistic regression) and multivariate analyses (binary logistic regression) to evaluate the total testosterone threshold and the symptoms that predicted a low-testosterone level. RESULTS: A cluster of symptoms: 1 sexual (decreased libido), 1 psychological (decreased energy), and 3 physical (decreased strength or endurance, decreased ability to play sports, and falling asleep after dinner) were most associated with total serum testosterone levels of ≤ 300 ng/dL. The threshold testosterone serum levels that were associated with an increased prevalence of these hypogonadal symptoms ranged from 320 to 375 ng/dL. On multivariate analysis, age, but not symptoms on the ADAM questionnaire, predicted a total testosterone level of < 300 ng/dL. CONCLUSION: A distinct constellation of hypogonadal symptoms exists at various serum testosterone levels. Consequently, identification of the thresholds for specific symptom management will be critical in establishing patient-centered treatment algorithms.
Authors: G Corona; E Mannucci; R Mansani; L Petrone; M Bartolini; R Giommi; M Mancini; G Forti; M Maggi Journal: Int J Impot Res Date: 2004-10 Impact factor: 2.896
Authors: Frederick C W Wu; Abdelouahid Tajar; Jennifer M Beynon; Stephen R Pye; Alan J Silman; Joseph D Finn; Terence W O'Neill; Gyorgy Bartfai; Felipe F Casanueva; Gianni Forti; Aleksander Giwercman; Thang S Han; Krzysztof Kula; Michael E J Lean; Neil Pendleton; Margus Punab; Steven Boonen; Dirk Vanderschueren; Fernand Labrie; Ilpo T Huhtaniemi Journal: N Engl J Med Date: 2010-06-16 Impact factor: 91.245
Authors: Joel S Finkelstein; Hang Lee; Sherri-Ann M Burnett-Bowie; J Carl Pallais; Elaine W Yu; Lawrence F Borges; Brent F Jones; Christopher V Barry; Kendra E Wulczyn; Bijoy J Thomas; Benjamin Z Leder Journal: N Engl J Med Date: 2013-09-12 Impact factor: 91.245
Authors: Shalender Bhasin; Glenn R Cunningham; Frances J Hayes; Alvin M Matsumoto; Peter J Snyder; Ronald S Swerdloff; Victor M Montori Journal: J Clin Endocrinol Metab Date: 2006-05-23 Impact factor: 5.958
Authors: Jakob E Lackner; Ernst Rücklinger; Georg Schatzl; Gerhard Lunglmayr; Christian W Kratzik Journal: BJU Int Date: 2011-01-13 Impact factor: 5.588
Authors: Raymond C Rosen; Andre B Araujo; Megan K Connor; Eric P Gerstenberger; Abraham Morgentaler; Allen D Seftel; Martin M Miner; Ridwan Shabsigh Journal: Clin Endocrinol (Oxf) Date: 2011-02 Impact factor: 3.478
Authors: Shalender Bhasin; Linda Woodhouse; Richard Casaburi; Atam B Singh; Ricky Phong Mac; Martin Lee; Kevin E Yarasheski; Indrani Sinha-Hikim; Connie Dzekov; Jeanne Dzekov; Lynne Magliano; Thomas W Storer Journal: J Clin Endocrinol Metab Date: 2004-11-23 Impact factor: 5.958
Authors: Jacques Baillargeon; Randall J Urban; Kenneth J Ottenbacher; Karen S Pierson; James S Goodwin Journal: JAMA Intern Med Date: 2013-08-12 Impact factor: 21.873